Keytruda and Bone lesion - a phase IV clinical study of FDA data

Summary:

Bone lesion is reported as a side effect among people who take Keytruda (pembrolizumab), especially for people who are male, 60+ old, have been taking the drug for 1 - 2 years also take Carboplatin, and have Lung neoplasm malignant.

The phase IV clinical study analyzes which people have Bone lesion when taking Keytruda. It is created by eHealthMe based on reports of 57,304 people who have side effects when taking Keytruda from the FDA, and is updated regularly.

What is Keytruda?

Keytruda has active ingredients of pembrolizumab. It is often used in renal cell carcinoma. eHealthMe is studying from 57,404 Keytruda users. Check the latest studies of Keytruda.

What is Bone lesion?

Bone lesion (bone with abnormalities. bone lesions can result from growth formations, infections, or injuries) is found to be associated with 853 drugs and 501 conditions by eHealthMe. Check the latest studies of Bone lesion.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 27, 2026

57,304 people reported to have side effects when taking Keytruda.
Among them, 19 people (0.03%) have Bone lesion.

Among these 19 people:

How long have people been on Keytruda when they have Bone lesion? *

What is the gender of people who have Bone lesion when taking Keytruda? *

female: 10.53 %
male: 89.47 %

What is the age of people who have Bone lesion when taking Keytruda? *

What are other drugs people take besides Keytruda? *

What are other side effects people have besides Bone lesion? *

Malignant Neoplasm Progression (cancer tumour came back): 12 people, 63.16%
White Blood Cell Count Decreased: 5 people, 26.32%
Pneumonia: 5 people, 26.32%
Ejection Fraction Decreased (systolic heart failure): 5 people, 26.32%
Thrombocytopenia (decrease of platelets in blood): 5 people, 26.32%
Fever: 5 people, 26.32%
Haemoglobin Decreased: 5 people, 26.32%
Inflammatory Marker Increased: 5 people, 26.32%
N-Terminal Prohormone Brain Natriuretic Peptide Increased: 5 people, 26.32%
Osteosclerosis (an elevation in bone density): 5 people, 26.32%

What are the existing conditions these people have? *

Lung Neoplasm Malignant (cancer tumour of lung): 6 people, 31.58%
Hypoaesthesia (reduced sense of touch or sensation): 3 people, 15.79%
Heart Attack: 3 people, 15.79%
Constipation: 3 people, 15.79%
Metastases To Bone (cancer spreads to bone): 2 people, 10.53%
Malignant Melanoma Stage Iii (cancer has spread to one or more lymph nodes): 2 people, 10.53%
Transitional Cell Carcinoma Metastatic (cancer of urinary inner most layer spreads to other part of body): 1 person, 5.26%
Thyroid Cancer: 1 person, 5.26%
Neoplasm Of Thymus (tumour of thymus): 1 person, 5.26%
Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 1 person, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take Keytruda and have Bone lesion?

- Check whether Bone lesion is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Keytruda:

Keytruda (57,404 reports)

Bone lesion treatments and more:

Bone lesion (6,686 reports)

Browse all side effects of Keytruda:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Bone lesion:

Bone lesion (853 drugs)

Browse all the conditions that are associated with Bone lesion:

Bone lesion (501 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on pembrolizumab (the active ingredients of Keytruda) and Keytruda (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.